Pharmaceutical Regulation, Bioethics and Healthcare Justice: A Critical Legal Analysis of Biologic Therapies and Insurance Accessibility in IBD Treatment in India
Inflammatory Bowel Disease (IBD) is a chronic disease that needs to be treated on an ongoing basis by a physician, and in some instances, by a high-level specialist in disease management. The development of biologic treatments has significantly enhanced the treatment of moderate to severe IBD by offering specific treatment options for patients who don't get enough benefit from conventional drugs. But the prices of biologic drugs and their restrictions in regulatory approval and availability in health insurance policies pose challenges to their access in India. In this paper, the connection between pharmaceutical regulation, bioethical concepts and healthcare justice to ensure access to biologic treatments is critically analysed. It follows a doctrinal and analytical legal research method using Indian pharmaceuticals laws, guidelines and regulations, intellectual property laws, health insurance laws and constitutional principles and precedents. The study explores the effectiveness of the regulatory framework and the current insurance schemes and the ethical issues presented by differential access to more sophisticated treatments. It believes that if the medicine is approved and marketed, it does not necessarily mean that there is some meaningful access to healthcare. A concerted effort with lower drug costs, appropriate biosimilar regulation and better insurance coverage and public healthcare support is required. The paper concludes that access to medically required biologic treatment is an integral part of a healthcare system's duty to "do justice" and should not come at the price of people's ability to afford it.
Authors
- Adv. Mrunal Dhamale
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-15
- DOI
- https://doi.org/10.5281/zenodo.24248810
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00